Tempus ECG-AF vs iPredict Eye Screening
AI Verdict
Choose Tempus ECG-AF if…
Choose Tempus ECG-AF if your primary objective is to proactively identify patients aged 65 or older who are at an increased risk of developing new-onset atrial fibrillation within the next 12 months, leveraging standard 12-lead ECG recordings. This tool is particularly well-suited for cardiology and internal medicine practices aiming to enhance early detection and follow-up strategies for AF in an asymptomatic, elderly population.
View Tempus ECG-AF →Choose iPredict Eye Screening if…
Choose iPredict Eye Screening if you need a comprehensive, AI-powered solution for simultaneous screening of multiple ocular diseases, including age-related macular degeneration, diabetic retinopathy, and glaucoma, in patients aged 50 and older. This platform is ideal for primary care, telemedicine, or ophthalmology settings that also seek to integrate risk prediction for systemic conditions like stroke and heart attack into their screening protocols.
View iPredict Eye Screening →Reviewed by Pouyan Golshani, MD — Interventional Radiologist
Quick Comparison
| Feature | Tempus ECG-AF | iPredict Eye Screening |
|---|---|---|
| Pricing | Contact vendor | Contact for pricing |
| Deployment | Software solution, integrated into healthcare facility systems with advanced cardiology algorithms. | Cloud-based (Software as a Medical Device), accessible in primary care settings, clinics, hospitals, and online for telemedicine and prediction apps. |
| BAA Available | Yes AI-estimated | Unknown |
| FDA Status | Yes AI-estimated | Cleared AI-estimated |
| HIPAA | Yes AI-estimated | Yes AI-estimated |
Head-to-Head
AI-generated assessment across six dimensions based on each tool's documented features and compliance posture. Grounded in public data — not a substitute for hands-on evaluation.
Usability
iPredict Eye ScreeningTool B explicitly highlights features like an 'easy to operate' interface, 'advanced touchscreen interface,' and 'fast results' (test in less than 5 minutes, report in under 60 seconds), suggesting a strong focus on user experience and efficient workflow. While Tool A mentions integration into existing systems, Tool B's description provides more concrete indicators of intuitive usability.
Clinical Value
iPredict Eye ScreeningTool B offers a broader range of clinical applications, screening for Diabetic Retinopathy, Age-related Macular Degeneration, and Glaucoma, in addition to providing risk prediction for systemic diseases like stroke and heart attack. Tool A, while valuable, focuses on a single condition: the risk of Atrial Fibrillation. Tool B also provides specific accuracy metrics for AMD screening.
Pricing & Value
iPredict Eye ScreeningTool B offers more pricing transparency by providing an estimated per-patient screening cost ($10-$20) on a Software as a Service (SaaS) model, which is presented as a percentage of potential reimbursement. While Tool A mentions CMS reimbursement rates, it only states 'contact vendor' for its own pricing, making it less transparent about the direct cost to the provider.
Enterprise Readiness
Tempus ECG-AFTool A explicitly states 'has_baa': 'yes', which is a critical legal and compliance requirement for healthcare enterprises handling Protected Health Information (PHI) under HIPAA. Although Tool B states it is HIPAA compliant, the lack of an explicit BAA statement in its specifications presents a potential hurdle for enterprise adoption compared to Tool A's clear affirmation.
Innovation
iPredict Eye ScreeningTool B demonstrates broader innovation by applying AI to multiple ophthalmic conditions (DR, AMD, Glaucoma) and extending its capabilities to include risk prediction for systemic diseases like stroke and heart attack, leveraging various imaging types. While Tool A's predictive AF risk from standard ECGs is innovative, Tool B's scope of AI application is more diverse and comprehensive.
Support & Docs
TieNeither the provided structured facts nor general web searches for publicly available information offer specific details regarding the level of support, documentation, or training resources provided by either Tempus AI for ECG-AF or iHealthScreen for iPredict Eye Screening. Without this information, it is not possible to distinguish between the two tools on this dimension.
Feature-by-Feature
Detail beyond the Quick Comparison summary. For pricing, deployment, BAA, FDA, and HIPAA see the Overview tab.
| Feature | Tempus ECG-AF | iPredict Eye Screening |
|---|---|---|
| Tool Name | Tempus ECG-AF | iPredict Eye Screening |
| Company | Tempus AI, Inc. | iHealthScreen |
| Primary Use Case | Identifies patients aged 65 or older at increased risk of developing atrial fibrillation/flutter (AF) within the next 12 months. | AI-powered screening for age-related macular degeneration (AMD), Diabetic Retinopathy (DR), and Glaucoma, with risk prediction for systemic diseases like stroke and heart attack. |
| Target Patient Age | 65 years or older | 50 years and older |
| Key Features (Selected) | AI-based algorithm for 12-lead ECG analysis; Detects signs associated with new onset Atrial Fibrillation (AF) within 12 months; Compatible with FDA authorized resting 12-lead ECGs from GE Medical Systems and Philips Medical Systems. | AI-Based Screening for Diabetic Retinopathy (DR), Age-related Macular Degeneration (AMD), and Glaucoma; Electronic Health Record (EHR) Solutions; AI-Based Telemedicine Service; Online Health Risk Prediction System for Diabetic, Stroke, and Heart Attack patients. |
Videos
Demos, reviews, and walkthroughs featuring Tempus ECG-AF and iPredict Eye Screening.